Physician profile
Michael C Muresan
NPI 1528387578
$1,010.67
in general payments reported to CMS, 2019-2025
15 companies · $23.83 in 2025
The $23.83 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.90 · 2020: $44.60 · 2021: $261 · 2022: $507 · 2023: $99.99 · 2024: $59.90 · 2025: $23.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $99.99 · Food and Beverage: $83.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $99.99 |
| Food and Beverage | $83.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $247.50 | 2022 | |
| Astellas Pharma US INC | $147.70 | 2023-2025 | Veozah |
| Abbvie INC. | $136.28 | 2019-2022 | |
| Ethicon US, LLC | $112.78 | 2022 | |
| Myovant Sciences INC. | $89.74 | 2021-2022 | |
| Hologic Sales and Service, LLC | $72.87 | 2022-2024 | Myosure Tissue Removal Device, Omni Hysteroscope |
| Therapeuticsmd, INC. | $33.79 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.39 | 2021-2022 | |
| Avion Pharmaceuticals | $26.48 | 2021-2022 | |
| Coopersurgical, INC. | $22.89 | 2022 | |
| Mayne Pharma Commercial LLC | $22.34 | 2021 | |
| Meditrina | $21.06 | 2020 | |
| Agile Therapeutics, INC. | $19.00 | 2021 | |
| Shield Therapeutics INC | $13.78 | 2022 | |
| Millicent US INC | $11.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Muresan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.